{"id":60437,"date":"2024-02-28T06:48:51","date_gmt":"2024-02-28T06:48:51","guid":{"rendered":"https:\/\/medsname.com\/rioci-1\/"},"modified":"2026-05-01T10:49:16","modified_gmt":"2026-05-01T10:49:16","slug":"rioci-1","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/rioci-1\/","title":{"rendered":"Rioci 1"},"content":{"rendered":"

<\/p>\n

\n

⚡ Quick Answer — What is Rioci 1?<\/h3>\n

Rioci 1<\/strong> is 1 mg riociguat tablets from a WHO-GMP certified manufacturer — a soluble guanylate cyclase (sGC) stimulator for plicn\u00ed arteri\u00e1ln\u00ed hypertenzi (PAH)<\/strong>. PAH je specifick\u00e9, progresivn\u00ed a vz\u00e1cn\u00e9 onemocn\u011bn\u00ed \u2014 nejde o tot\u00e9\u017e co syst\u00e9mov\u00e1 hypertenze<\/strong>. It raises pressure in the pulmonary arteries, not the systemic arteries, and requires dedicated specialist-directed therapy at an accredited PAH centre. Riociguat was introduced by Bayer in 2013 as Adempas<\/strong> — the first sGC stimulator approved for human use. FDA-approved for two specific forms of pulmonary hypertension: pulmonary arterial hypertension (PAH, WHO Group 1) and chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 4) — the only oral drug approved for inoperable CTEPH. directly activates soluble guanylate cyclase (the NO receptor) in pulmonary arterial smooth muscle, raising cGMP and producing pulmonary vasodilation. Unlike PDE5 inhibitors, riociguat stimulates sGC even in the absence of NO, giving activity in NO-deficient vascular beds characteristic of PAH and CTEPH. Dosing: Start 1 mg three times daily (8-hour intervals); titrate every 2 weeks by 0.5 mg increments based on systolic BP (must remain >95 mmHg) and symptoms. Target dose 2.5 mg three times daily. PAH treatment is typically combination therapy initiated and monitored at a specialist centre; this is not a DIY disease.<\/p>\n<\/div>\n

\nCo z\u00edsk\u00e1te s MedsBase:<\/strong> V\u00fdrobce certifikovan\u00fd WHO-GMP \u00b7 Diskr\u00e9tn\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 doprava \u00b7 V\u00edce ne\u017e 1 400 ov\u011b\u0159en\u00fdch recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a>\n<\/div>\n

\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n

Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n

Na\u0161e generick\u00e9 l\u00e9ky poch\u00e1zej\u00ed od v\u00fdrobc\u016f certifikovan\u00fdch WHO-GMP a jsou expedov\u00e1ny po cel\u00e9m sv\u011bt\u011b v diskr\u00e9tn\u00edm, nen\u00e1padn\u00e9m balen\u00ed \u2013 na vn\u011bj\u0161\u00ed stran\u011b bal\u00edku nen\u00ed uveden n\u00e1zev l\u00e9ku. Platby kartou jsou sm\u011brov\u00e1ny prost\u0159ednictv\u00edm regulovan\u00e9ho procesoru (popisky na v\u00fdpisu zahrnuj\u00ed regulovan\u00e9ho procesora plateb kartou \u2013 nikdy \u201cMedsBase\u201d nebo n\u00e1zev l\u00e9ku). P\u0159ij\u00edm\u00e1me tak\u00e9 kryptom\u011bny a bankovn\u00ed p\u0159evody SEPA. Ka\u017ed\u00e1 objedn\u00e1vka je zaji\u0161t\u011bna na\u0161\u00ed politikou p\u0159eposl\u00e1n\u00ed.<\/p>\n

What Is Rioci 1?<\/h2>\n

Rioci 1 is 1 mg riociguat tablets from a WHO-GMP certified manufacturer, supplied in 10-180 tablets. Riociguat was introduced by Bayer in 2013 as Adempas<\/strong> — the first sGC stimulator approved for human use. FDA-approved for two specific forms of pulmonary hypertension: pulmonary arterial hypertension (PAH, WHO Group 1) and chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 4) — the only oral drug approved for inoperable CTEPH.<\/p>\n

Plicn\u00ed arteri\u00e1ln\u00ed hypertenze (PAH) nen\u00ed syst\u00e9mov\u00e1 hypertenze.<\/strong> PAH se konkr\u00e9tn\u011b t\u00fdk\u00e1 zv\u00fd\u0161en\u00e9ho tlaku v plicn\u00edm arteri\u00e1ln\u00edm ob\u011bhu (\u226520 mmHg st\u0159edn\u00ed tlak v plicnici s plicn\u00ed vaskul\u00e1rn\u00ed rezistenc\u00ed \u22652 Woodovy jednotky dle sm\u011brnic ESC\/ERS z roku 2022). Je to vz\u00e1cn\u00e9 onemocn\u011bn\u00ed (odhadovan\u00fd v\u00fdskyt 15\u201350 na milion dosp\u011bl\u00fdch), progresivn\u00ed a bez l\u00e9\u010dby m\u00e1 \u0161patnou progn\u00f3zu (historick\u00e9 5let\u00e9 p\u0159e\u017eit\u00ed \u223c30 %). Modern\u00ed terapie c\u00edlen\u00e1 na PAH zlep\u0161ila 5let\u00e9 p\u0159e\u017eit\u00ed na 60\u201370 % ve specializovan\u00fdch centrech.<\/p>\n

Candidates for Rioci 1 have been diagnosed at a PAH specialist centre via right heart catheterisation, with WHO\/NYHA functional class II-IV symptoms and confirmed PAH (WHO Group 1) or — for riociguat — inoperable or persistent CTEPH (WHO Group 4). This is not a drug for ordinary hypertension or for self-initiated therapy.<\/p>\n

How Riociguat Works<\/h2>\n

Directly activates soluble guanylate cyclase (the NO receptor) in pulmonary arterial smooth muscle, raising cGMP and producing pulmonary vasodilation. Unlike PDE5 inhibitors, riociguat stimulates sGC even in the absence of NO, giving activity in NO-deficient vascular beds characteristic of PAH and CTEPH.<\/p>\n

D\u016fkazy<\/h2>\n

PATENT-1 (2013)<\/strong> — riociguat in 443 PAH patients; 6-minute walk distance improved by 30 m vs placebo, with better WHO functional class and delayed clinical worsening. CHEST-1 (2013)<\/strong> — riociguat in 261 inoperable or persistent CTEPH patients; 6-minute walk improved by 46 m vs placebo.<\/p>\n

D\u00e1vkov\u00e1n\u00ed a monitorov\u00e1n\u00ed<\/h2>\n

D\u00e1vkov\u00e1n\u00ed:<\/strong> Start 1 mg three times daily (8-hour intervals); titrate every 2 weeks by 0.5 mg increments based on systolic BP (must remain >95 mmHg) and symptoms. Target dose 2.5 mg three times daily.<\/p>\n

Monitorov\u00e1n\u00ed:<\/strong> P\u0159i zah\u00e1jen\u00ed l\u00e9\u010dby a ka\u017ed\u00e9 3\u20136 m\u011bs\u00edce pot\u00e9 \u2014 funk\u010dn\u00ed t\u0159\u00edda WHO, 6minutov\u00e1 vzd\u00e1lenost ch\u016fze, NT-proBNP, opakovan\u00e1 echokardiografie a (v del\u0161\u00edch intervalech) pravostrann\u00e1 katetrizace srdce. V\u0161e prov\u00e1d\u011bno ve specializovan\u00e9m centru pro PAH.<\/p>\n

BP monitoring:<\/strong> systolic BP must remain >95 mmHg; uptitration paused or reversed on symptomatic hypotension.<\/p>\n

Vedlej\u0161\u00ed \u00fa\u010dinky<\/h2>\n